{"id":51009,"date":"2025-12-16T23:39:06","date_gmt":"2025-12-16T15:39:06","guid":{"rendered":"https:\/\/flcube.com\/?p=51009"},"modified":"2025-12-16T23:39:08","modified_gmt":"2025-12-16T15:39:08","slug":"saizeng-medical-licenses-tshr-antibody-to-yarrow-for-1-4b-in-graves-disease-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51009","title":{"rendered":"Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal"},"content":{"rendered":"\n

Saizeng Medical Technology Co. Ltd<\/strong>, a subsidiary of Changchun High\u2011Tech Industry (Group) Co., Ltd.<\/strong> (SHE: 000661<\/a>), entered into an exclusive licensing agreement with Yarrow Bioscience, Inc.<\/strong> for GenSci098 injection<\/strong>, a humanized monoclonal antibody targeting the Thyroid Stimulating Hormone Receptor (TSHR)<\/strong>. GenSci will receive $120 million in near\u2011term payments<\/strong> and up to $1.365 billion in milestones<\/strong>, plus royalties exceeding 10%<\/strong> of net sales.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Licensee<\/strong><\/td>Yarrow Bioscience, Inc.<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD 70 million<\/td><\/tr>
Near\u2011Term Milestones<\/strong><\/td>USD 50 million<\/td><\/tr>
Total Near\u2011Term<\/strong><\/td>USD 120 million<\/strong><\/td><\/tr>
Total Potential Milestones<\/strong><\/td>Up to USD 1.365 billion<\/strong><\/td><\/tr>
Royalties<\/strong><\/td>>10% of net sales post\u2011launch<\/td><\/tr>
Asset<\/strong><\/td>GenSci098 injection (TSHR antagonist)<\/td><\/tr>
Indications<\/strong><\/td>Thyroid\u2011Associated Ophthalmopathy (TED) and Graves\u2019 Disease (GD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile<\/h2>\n\n\n\n
Attribute<\/th>GenSci098<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Humanized monoclonal antibody TSHR antagonist<\/td><\/tr>
Innovation<\/strong><\/td>Category 1 therapeutic biologic<\/strong> (first\u2011in\u2011class in China)<\/td><\/tr>
Action<\/strong><\/td>Blocks autoantibody binding to TSHR, inhibits thyroid hormone synthesis, prevents hyaluronic acid\/inflammatory factor release<\/td><\/tr>
Benefits<\/strong><\/td>Improves hyperthyroidism and mitigates proptosis (bulging eyes)<\/td><\/tr>
Stage<\/strong><\/td>Clinical development for TED and GD\u2011related indications<\/td><\/tr>
Administration<\/strong><\/td>Injectable<\/td><\/tr>
IP Status<\/strong><\/td>Independently developed by GenSci Medical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
TED Prevalence<\/strong><\/td>~1 million patients globally<\/td>~30% of Graves’ disease patients develop TED<\/td><\/tr>
Graves’ Disease<\/strong><\/td>~20 million patients worldwide<\/td>Significant unmet need for disease\u2011modifying therapy<\/td><\/tr>
Current Treatments<\/strong><\/td>Tepezza (IGF\u20111R inhibitor) dominates TED market<\/td>TSHR approach is novel mechanism<\/td><\/tr>
Peak Sales Potential<\/strong><\/td>$2\u20113 billion<\/strong> global (if approved)<\/td>Addresses both TED and underlying GD<\/td><\/tr>
Competitive Advantage<\/strong><\/td>First TSHR\u2011targeted therapy<\/strong><\/td>Differentiated from IGF\u20111R pathway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n